12-15 November, 2018
Marriott Marquis & Marina, San Diego, CA

ADC & IO Combo Day

 

08.00 Chair’s Opening Remarks
Shyra Gardai, Director of Immunology, Seattle Genetics
08.10                                                                                      Rapid Advancements of Oncology Landscape: A Review of ADC & Immuno-Oncology

  • The current landscape of IO
  • The clinical landscape of IO plus ADC
  • How philanthropic investment model help advance the IO combo trials move forward
Jun Tang, Senior Analyst, Cancer Research Institute

Improving Understanding of Scientific Rationale for Effective Combination Therapies

08.40

 

 

 

Mirvetuximab Soravtansine: Where do ADC Sit in an Immuno-Oncology World?

  • Introduction to ImmunoGen and Mirvetuximab Soravtansine
  • Exploring antitumor activity of Mirvetuximab Soravtansine as a single agent
  • Understanding antitumor activity in combination with Pembrolizumab
Karim Malek, Medical Director, ImmunoGen 

09.10

 

Speed Networking

 

10.00

 

 Morning Refreshments & Networking

 

Improving Understanding of Scientific Rationale for Effective Combination Therapies

       10.30

 


Improving Our Understanding of the Scientific Rationale & Mechanisms of Action for ADC & Immuno-Oncology Combination Therapies

  • Non-clinical data to support combinations of ADC and IO agents
  • Preclinical models to support ADC and IO combinations
  • Selection of ADC targets for IO combination strategies

Leslie Sharp, Vice President, Immuno-Oncology, BioAtla

 

 11.00

 

 

 

Think Tank Roundtable Sessions

More practical and highly interactive breakout roundtables where attendees can crowd-source solutions and share opinions around pre-assigned topic areas. A valuable chance for attendees to unite around hot topics and debate best practice. No more sitting quietly, this is a dedicated opportunity for you to voice your experiences and identify unique solutions.

 11.30

 

 

 

Moderator Feedback & Audience Debate

Moderators will be assigned to each roundtable to facilitate discussion and collate the findings. Following the roundtables, they will present back to the entire delegation as part of a panel discussion for information dissemination.

 12.00 Lunch & Networking

Preclinical & Clinical Learnings of ADC & Immune Checkpoint Modulator Combinations

13.00

 

 

 

 

 

 

 

 

Head-to-head Comparison of Non-Internalizing ADC & SMDC Products, Alone & in

Combination with Antibody-IL2 Fusion Proteins

  • Explore experimental evidence that suggests it may be possible to have efficacy with an extracellular release of the toxic drug
  • Carbonic Anhydrase IX is a non-internalizing cell membrane-protein overexpressed in tumor hypoxia and in certain malignancies, targeted in patients with radionuclide conjugates and with an ADC product
  • Insight into how Acetazolamide exhibits a high binding affinity to CAIX. Acetazolamide based SMDC products may represent an alternative to ADC products for the treatment of CAIX-positive solid tumors, as single agents or in combination with immunocytokines

Samuele Cazzamalli, Research Scientist, Philochem

 

13.30

 

Preclinical Update & Clinical Plan of Topoisomerase I Inhibitor, Exatecan Derivative-Based ADCs (DXd-ADC) with IO Combination

  • Overviews of DXd-ADC technology
  • Preclinical updates of DXd-ADC franchise
  • Clinical plans of DXd-ADC franchise

Hirokazu Suzuki, Researcher, Biologics & Immuno-Oncology Laboratories, Daiichi Sankyo

 

14.00

 

Case Study: Bridging Preclinical & Clinical Data for ADC & IO Combo Trials

  • Discuss preclinical data that suggests that Brentuximab vedotin and Ladiratuzumab vedotin drive immunogenic cell death
  • Review biomarker data from clinical trials of BV in Hodgkin lymphoma and LV in breast cancer supports the induction of inflammatory cytokines and innate inflammatory responses which are consistent with MMAE-induced ICD
  • Insight from how our data supports an additional mechanism of action for BV and LV and provides the rationale for combining our ADCs with immuno-oncology therapies including PD-L1 checkpoint blockade antibodies in ongoing clinical trials
Shyra Gardai, Director of Immunology, Seattle Genetics  

 14.30

 

Afternoon Refreshments & Networking

 

The Future: Evaluating Future Development of ADC & IO Combinations

 15.00

 

 

 

 

Investigational ADCs & Combination Regimens for Treatment of B-cell Malignancies

  • Review investigational ADC in clinical testing for non-Hodgkin lymphoma and multiple myeloma
  • Review rationale for antigen targeting
  • Review rationale for ongoing combination studies

Arturo Molina, Chief Medical Officer, Sutro BioPharma

 

 15.30

 

 

Panel Discussion: Challenges & Opportunities with ADC & IO Combos

  • Lessons learned from progress in the field so far
  • Evaluating opportunities over the next 12 months
  • How do different stakeholders need to contribute?

Panellists will be a selection of experts

 

 16.00 Chair’s Closing Remarks
Shyra Gardai, Director of Immunology, Seattle Genetics